Jagannadha Sastry

Dr. Jagannadha Sastry

Department of Immunology and Department of Veterinary Sciences, The University of Texas MD Anderson Cancer Center, Room: SCR4.2013, Unit 902, 7455 Fannin, Houston, TX 77054, USA

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2008 in Cancer Research
Verified
Journal Article
Closed access
PDF file
FWFeng Wang-Johanning
Feng Wang-Johanning
LRLaszlo Radvanyi
Laszlo Radvanyi
KRKiera Rycaj
Kiera Rycaj
JPJoshua B. Plummer
Joshua B. Plummer
PYPeisha Yan
Peisha Yan
GJGary L. Johanning
Gary L. Johanning
Recent evidence indicates that human cancer cells reactivate the expression of latent human endogenous retroviral (HERV) proteins. However, the extent to which cancer patients mount de novo immune responses against expressed HERV elements is unclear. In this study, we determined the extent of HERV-K env expression in human breast cancer (BC) and whether both humoral and cell-mediated immunity against HERV-K can be found in BC patients. We found HERV-K env protein expression in 88% of BC (n = 119) but not in normal breast (n = 76) tissues. ELISA screening assays detected significant titers of anti–HERV-K env IgG in a large proportion of BC patients. T-cell responses against HERV-K were also detected in peripheral blood mononuclear cells (PBMC) from BC patients stimulated with autologous dendritic cells pulsed with HERV-K env SU antigens. These responses included induction of T-cell proliferation (P = 0.0043), IFN-γ production measured by enzyme-linked immunospot (P < 0.0001), and multiplex cytokine secretion (P = 0.0033). Multiplex cytokine analysis found a T-helper 1 cytokine response, including interleukin (IL)-2 (P = 0.0109), IL-6 (P = 0.0396), IL-8 (P = 0.0169), and IP-10 (P = 0.0045) secretion during in vitro stimulation of BC PBMC with HERV-K antigen. We also found HERV-K–specific CTLs that were capable of lysing target cells expressing HERV-K env protein in BC patients but not in normal female controls without cancer. These findings suggest that retroviral gene products are capable of acting as tumor-associated antigens activating both T-cell and B-cell responses in BC patients. [Cancer Res 2008;68(14):5869–77]

18 September 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
SDStephanie Dorta-Estremera
Stephanie Dorta-Estremera
VHVenkatesh L. Hegde
Venkatesh L. Hegde
RSRavaen B. Slay
Ravaen B. Slay
RSRachel Sun
Rachel Sun
AYAnanta V. Yanamandra
Ananta V. Yanamandra
JSJagannadha Sastry
Jagannadha Sastry
Background The US is experiencing an epidemic of HPV+ oropharyngeal cancers (OPC), the rates and burden of which now exceed that for cervical cancer. Immunotherapy targeting programmed death 1 (PD-1) on tumor-infiltrating lymphocytes and/or its ligand PD-L1 on tumor cells, which was effective in several cancers has however, showed efficacy in only less than 15% of patients. Methods We used a preclinical HPV+ oral tumor model, mEER, consisting of mouse tonsil derived epithelial cells expressing HPV-16 E6 and E7 genes, along with the H-ras oncogene to test strategies for enhancing the efficacy of anti-PD-1 therapy. Results Monotherapy with PD-1 blocking antibody was ineffective against flank-implanted tumors, but induced regression in 54% of mice bearing orthotopic tongue tumors that correlated with higher CD8 T cell responses. Since the CD8+ T cells derived from tongue tumors also showed high levels of the immune checkpoint inhibitory receptor CTLA-4, we tested combination immunotherapy targeting both CTLA-4 and PD-1 together and observed 93.3% survival of mice bearing tumors in the tongue for the duration of our 100-day study. Protective immunity correlated with a significant decrease in immunosuppressive lymphoid and myeloid populations within the tumor microenvironment. Consistent with the reported capacity of interferon-driven PD-L1/PD-1 pathway induction to serve as a biomarker of response to PD-1 blockade, we observed elevated interferon signaling and significantly higher levels of PD-1/PD-L1 in tongue-implanted mEER tumors compared to those growing on the flank correlating with their preferential responsiveness to PD-1 blockade. More importantly, in a pseudometastasic mouse model bearing both flank and tongue tumors to represent metastatic disease, delivery of Stimulator of Interferon Induced Genes (STING) agonist into the flank tumors combined with systemic treatment with α-PD-1 and α-CTLA-4 antibodies resulted in sustained tumor regression in 71% of mice. In this case, productive abscopal anti-tumor immunity was associated with robust increases in the ratios of cytotoxic CD8+ T cells (CTL) versus regulatory T cells (Treg) and versus functional myeloid-derived suppressor cells (MDSC). Conclusions These results support combining α-PD-1 therapy with induction of IFN-α/β signaling via provision of STING agonist and/or through CTLA-4 blockade as potential treatment option for HNSCC patients, especially, those not responding to α-PD-1 monotherapy.

1 October 2010 in Virology
Verified
Journal Article
Closed access
MLMargarita K. Lay
Margarita K. Lay
RARobert L. Atmar
Robert L. Atmar
Susana GuixSusana Guix
Susana Guix
UBUddalak Bharadwaj
Uddalak Bharadwaj
HHHong He
Hong He
MEMary K. Estes
Mary K. Estes

8 September 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TBTodd Bartkowiak
Todd Bartkowiak
SSShailbala Singh
Shailbala Singh
GYGuojun Yang
Guojun Yang
GGGloria Galvan
Gloria Galvan
DHDhwani Haria
Dhwani Haria
MCMichael A. Curran
Michael A. Curran
Significance: Nearly all cervical, anal, vulvar, and penile cancer and up to half of oropharyngeal cancers are driven by the E6 and E7 oncoproteins of human papilloma virus (HPV). Therapeutic vaccination against these HPV proteins can slow disease progression in animal models and in patients, but is rarely curative. We demonstrate that coadministration of agonist antibodies targeting the T-cell costimulatory receptor 4-1BB and an intranasal HPV E6/E7 peptide vaccine promoted durable regression in 100% of animals bearing HPV + TC-1 tumors established in the female reproductive tract. The efficacy of 4-1BB in this system was unique among immune checkpoint antibodies and provides a paradigm for enhancement of therapeutic cancer vaccines with costimulatory agonist antibodies.

1 May 2000 in Applied Animal Behaviour Science
Verified
Journal Article
Closed access
SSSteven J Schapiro
Steven J Schapiro
PNPramod N. Nehete
Pramod N. Nehete
JPJaine E. Perlman
Jaine E. Perlman
JSJagannadha Sastry
Jagannadha Sastry

26 May 2009 in Vaccine
Verified
Journal Article
Closed access
PTPrakash Thapa
Prakash Thapa
GZGuodong Zhang
Guodong Zhang
CXChengfeng Xia
Chengfeng Xia
AGAlexander Gelbard
Alexander Gelbard
WOWillem W Overwijk
Willem W Overwijk
DZDapeng Zhou
Dapeng Zhou